MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4100
-0.0020
-0.49%
After Hours: 0.4184 +0.0084 +2.05% 19:37 07/30 EDT
OPEN
0.4133
PREV CLOSE
0.4120
HIGH
0.4264
LOW
0.4100
VOLUME
1.95M
TURNOVER
--
52 WEEK HIGH
1.570
52 WEEK LOW
0.2639
MARKET CAP
59.71M
P/E (TTM)
-1.4882
1D
5D
1M
3M
1Y
5Y
Report 2021, Cervical Cancer Screening Market | Global Size, Share, Growth, Trends, Revenue Analysis, Competitive Landscape, Forecast 2028
The global cervical cancer screening market size is expected to gain momentum owing to the increasing prevalence of cancer during the forecast period. This information is published by Fortune Business Insights(TM) in an upcoming report, titled, "Cervical C...
GlobeNewswire · 07/22 06:58
Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy
Benzinga · 07/15 12:53
BRIEF-Advaxis Announces Initiation Of Phase 1 Clinical Trial Of ADXS-504 For Treatment Of Early Prostate Cancer
reuters.com · 07/15 12:41
Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indicationMONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the devel...
GlobeNewswire · 07/15 12:00
Advaxis Starts Phase 1 Trial of Early Prostate Cancer Therapy
MT Newswires · 07/15 09:49
Advaxis To Present At The Non-Small Cell Lung Cancer Drug Development Summit Jul. 15
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and
Benzinga · 07/14 20:04
Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit
PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice ...
GlobeNewswire · 07/14 20:01
SeaSpine Lauded by Analysts After Spine Module Cleared by FDA
The Food and Drug Administration's cleared SeaSpine's 7D Percutaneous Spine Module for spinal surgery. The company's shares are higher.
TheStreet.com · 07/08 12:57
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADXS. Analyze the recent business situations of Advaxis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADXS stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 10.75M
% Owned: 7.38%
Shares Outstanding: 145.64M
TypeInstitutionsShares
Increased
12
4.18M
New
9
329.21K
Decreased
8
4.23M
Sold Out
8
1.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Non-Executive Chairman/Independent Director
David Sidransky
President/Chief Executive Officer/Chief Financial Officer/Director
Kenneth Berlin
Non-Executive Vice Chairman/Independent Director
James Patton
Executive Vice President
Andres Gutierrez
Chief Accounting Officer/Vice President - Finance
Igor Gitelman
Independent Director
Roni Appel
Independent Director
Richard Berman
Independent Director
Samir Khleif
No Data
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.